UCP2 acts as a potential prognostic marker in AML. (IMAGE)
Caption
(A) TGCA database analysis of UCP2 mRNA level in healthy donors identified in the gray box (n = 70) versus AML patients identified with the red box (n = 173). (B) Kaplan–Meier plot of UCP2 overall survival in the low-risk versus high-risk AML group. (C) Quantitative PCR of UCP2 mRNA level in a panel of AML cell lines versus either peripheral blood (PBL) or bone marrow (BM) normal controls. (D) Time-dependent receiver operating characteristic curve according to the 1-year, 3-year, and 5-year survival of the area under the curve (AUC value). (E) Immunoblotting of UCP2 protein level in a panel of AML primary cells (n = 10) versus healthy donors (n = 2). Band intensity was measured using the Image J software and normalized to GAPDH control. (F) Quantitative PCR of UCP2 mRNA level in de novo AML primary cells (n = 18) versus paired relapsed AML primary cells (n = 18). All experiments were repeated three times. Data represent mean ± standard deviation from technical triplicates (∗p < 0.01, ∗∗p < 0.05, and ∗∗∗p < 0.001; Two-way ANOVA for BM or PBL controls versus cell lines, unpaired t-test for the normal versus AML and the de novo versus the relapse). UCP2, uncoupling protein 2; AML, acute myeloid leukemia.
Credit
Agida Okohi Innocent, Yajie Shen, Yixuan Gao, Ruixin Sun, Kasimujiang aximujiang, Zizhen Xu, Jinke Cheng, Jiao Ma
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND